APPLICATION
NDA218709
TYPE
NDA
ORIGINAL APPROVAL
2024-04-26
LATEST ACTION
2024-04-26
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription
Products
XOLREMDI · ReferencePrescription
MAVORIXAFOR 100MG · CAPSULE · ORAL
Approval history
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.